Treatment of Adult Acute Myeloblastic Leukemia
The introduction of combination chemotherapy in the treatment of adult acute leukemia has had a profound impact on the response and duration of survival of patients with adult acute myeloblastic leukemia. In the past decade, the combination of cytosine arabinoside with an anthracycline antibiotic, either daunorubicin, adriamycin, or rubidazone, has been responsible to a large degree for the success.
KeywordsComplete Remission Acute Leukemia Cytosine Arabinoside Autologous Bone Marrow Transplantation Acute Myeloblastic Leukemia
Unable to display preview. Download preview PDF.
- 3.Keating, M.J., Benjamin, R.S., McCredie, K.B., Bodey, G.P., Freireich, E.J.: Remission induction therapy with a rubidazone-containing combination (ROAP) in acute leukemia. P. 180. Proceedings of the 68. Annual Meeting of AACR/ASCO. 1977. Abstract No. 719Google Scholar
- 4.McCredie, K.B., Freireich, E.J.: Acute leukemia: Chemotherapy and Management. In: Clinical cancer chemotherapy. Greenspan, E.M. (ed.). pp. 71–109. New York: Raven Press 1975Google Scholar
- 5.McCredie, KB., Hewlett, J.S., Gehan, E.A., Freireich, E.J.: Chemoimmunotherapy of adult acute leukemia (CIAL). p. 127. Proceedings of the 68. Annual Meeting of the AACR/ ASCO. 1977. Abstract No. 506Google Scholar